KELLY

THIS A MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO ASSESS THE EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH ERIBULIN IN FEMALE PATIENTS OLDER THAN 18 YEARS OLD WITH HORMONE RECEPTOR-(HR)POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH AT LEAST ONE, BUT NOT MORE THAN TWO, PRIOR CHEMOTHERAPEUTIC REGIMENS FOR TREATMENT OF LOCALLY RECURRENT AND/OR METASTATIC DISEASE. PRIOR THERAPY MUST HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE. PRIOR ANTI-HORMONAL THERAPY IN THE METASTATIC DISEASE SETTING IS MANDATORY. THE NUMBER OF PATIENTS TO BE INCLUDED IS 44 PATIENTS AT 11 SITES. ALL ELIGIBLE PATIENTS WILL BE TREATED WITH MK3475 (PEMBROLIZUMAB) 200 MG ON DAY 1 OF EACH 21-DAY CYCLE AND ERIBULIN 1.23 MG/M2 ON DAYS 1 AND 8 OF EVERY 21-DAY CYCLE.